AlzeCure will present at Redeye’s Neurology Day

AlzeCure Pharma develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer’s disease and pain. The company announced that CEO Martin Jönsson will present at Redeye’s Neurology Day at 11 a.m. on October 23.

In the presentation, which is made in English, Martin Jönsson will focus on the company’s projects in Alzheimer’s disease – Alzstatin and NeuroRestore, including the lead drug candidate ACD856, which is in clinical development and being prepared for phase 2, with a focus on improving learning and memory capacity. The presentation is followed by a Q&A led by a Redeye analyst.

The live broadcast is available via the following link: https://www.redeye.se/events/1016173/redeye-theme-neurology-2 and will then be posted on the company’s website.